ARCTURUS THERAPEUTICS HLDGS's ticker is ARCT and the CUSIP is 03969T109. A total of 156 filers reported holding ARCTURUS THERAPEUTICS HLDGS in Q3 2021. The put-call ratio across all filers is 0.65 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $35,617 | -10.9% | 1,394 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $39,980 | +19.7% | 1,394 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $33,414 | +41.3% | 1,394 | 0.0% | 0.00% | +100.0% |
| Q4 2022 | $23,642 | +14.4% | 1,394 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $20,659 | -5.8% | 1,394 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $21,942 | -41.6% | 1,394 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $37,582 | -83.9% | 1,394 | -77.9% | 0.00% | -66.7% |
| Q4 2021 | $233,496 | -22.5% | 6,309 | 0.0% | 0.00% | -25.0% |
| Q3 2021 | $301,444 | +42.6% | 6,309 | +1.0% | 0.00% | +33.3% |
| Q2 2021 | $211,398 | -18.1% | 6,247 | 0.0% | 0.00% | -25.0% |
| Q1 2021 | $258,001 | -4.8% | 6,247 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $270,995 | +33.5% | 6,247 | +32.1% | 0.00% | 0.0% |
| Q3 2020 | $202,917 | +4.0% | 4,730 | +13.3% | 0.00% | +33.3% |
| Q2 2020 | $195,093 | – | 4,174 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SEVEN EIGHT CAPITAL, LP | 46,819 | $2,031,000 | 0.47% |
| Orbimed Advisors | 1,206,886 | $49,844,000 | 0.47% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 25,000 | $1,033,000 | 0.40% |
| ARK Investment Management | 3,331,889 | $137,607,000 | 0.27% |
| FEDERATED HERMES, INC. | 3,203,000 | $132,284,000 | 0.26% |
| MGO ONE SEVEN LLC | 26,990 | $1,114,000 | 0.19% |
| Koss-Olinger Consulting, LLC | 20,000 | $826,000 | 0.14% |
| Jump Financial, LLC | 35,400 | $1,462,000 | 0.14% |
| Graham Capital Management, L.P. | 74,262 | $3,067,000 | 0.14% |
| New England Research & Management, Inc. | 6,005 | $248,000 | 0.14% |